FOR IMMEDIATE RELEASE: 1 November 2022
Nearly 70% of Life-Sci hiring is in the last quarter of the year
Biotech Search in 6-8 weeks means you can secure talent by end 2022
• From our sector experience the majority of recruitment is done in the last quarter
• Our specialist bespoke talent search solves the annual rush to make offers (and get acceptances) by December
• We do the heavy lifting in our Biotech Search package to get you where you need to be in 6-8 weeks
PhoreMost enters multi-target collaboration with targeted protein degradation leader Arvinas
PhoreMost to deploy its SITESEEKER® Targeted Protein Degradation platform to enable drug discovery against multiple therapeutic targets
MD-T is proud sponsor of Fierce European TMF Summit. This is an excellent opportunity for organisations to share tools, strategies and methodologies to help over come dynamic TMF challenges.
Come meet the MD-T team at our booth and discuss the concerns your organisation may be facing to comply and implement the GDPR, UK Data Protection Act or any other international data protection regulation.
Check out this month's People Pathways newsletter for your monthly round-up of employee engagement activities.
AMSBIO has added a new range of Vesicular Stomatitis Virus (VSV) to its suite of virus-based tools for cell engineering and the study of viral infection.
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has announced the formation of a new subsidiary company, Cytolytix Limited, which has signed an IP license agreement with Kings College London to progress the preclinical development of its triple negative breast cancer treatment, CLX001.
Triple negative breast cancer accounts for around 15% of breast cancers. It is usually more aggressive, harder to treat, and more likely to recur than many other cancers.
Asahi Kasei Pharma has announced the new application period for their annual “Open Innovation” solicitation of proposals for drug discovery research. Through collaboration with universities, research institutes, and companies around the world, Asahi Kasei Pharma has been supporting innovation in drug discovery since 2018 and will fund up to $200,000 US per year for each selected proposal of the upcoming round in 2023.
Takeda UK, in partnership with The ADHD Foundation and Eastern AHSN (Academic Health Science Network), is launching a call for applications to our newest digital challenge to benefit patients who have Attention Deficit Hyperactivity Disorder (ADHD). What can Takeda offer?
Life science specialists – AMSBIO offer an extensive range of highly characterized, high purity exosomes for use as control standards in applications including marker assessment, immunocapture performance evaluation, exosome quantification, OMICS analysis, flow cytometry and electron microscopy.
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has appointed Stella Panu as non-executive director.
With over 20 years’ experience in corporate finance and investment management, Stella’s expertise will support the ValiRx Board and senior management team to unlock investment potential and accelerate and manage business growth for the company.
In her role, she will also oversee ValiRx’s M&A activity, advising on corporate structure and governance, risk management, and shareholders’ rights.